Trials / Completed
CompletedNCT00038025
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.
Detailed description
Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deoxycoformycin (DCF) | Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals. |
Timeline
- Start date
- 1994-09-06
- Primary completion
- 2006-11-29
- Completion
- 2006-11-29
- First posted
- 2002-05-27
- Last updated
- 2018-11-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00038025. Inclusion in this directory is not an endorsement.